Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity.

Roos J JuttenSietske A M SikkesWiesje Maria van der Flier Philip Scheltens Pieter Jelle Visser Betty M Tijmsnull null

Published in: Neurology (2021)

Individuals with early AD show heterogeneity in disease progression, which increases when stratifying on risk factors associated with progression. We provide guidance for a priori effect sizes on cognitive outcomes for detecting true change, which is crucial for future AD trials.

Keyphrases

single cell
cognitive decline
current status
type diabetes
adipose tissue
glycemic control